London-listed recorded ‘a strong finish’ to the financial year with a trading update for the year ending 31 December 2019.
The company, which provides services to the global pharmaceutical industry, said a wider client base and a surge in product sales were responsible for a strong trading performance in its final quarter.
As a result, the group has said it expects revenue and adjusted EBITDA to be ahead of market expectations.
The statement recorded revenue at around £13.4 million for 2019 up from £10.4 million in the previous year, whilst EBITDA is expected to exceed £2.1 million compared to £1.5 million in 2018.
“2019 was a key year in expanding our global footprint and deepening our service relationships with key clients and their therapy brands,” said Peter Keeling, Chief Executive of Diaceutics.
Shares in Diaceutics were trading 13.24% at 115.5p on Monday afternoon.
Diaceutics also reported all outstanding debt to be retired from the balance sheet, resulting in net cash of £11.7 million which will enable the group to ‘expand globally’.
A considerable rise from £2 million in the previous year, the net cash sum will also go towards the group’s preparation for the launch of the Nexus platform later this year, the company highlighted.
The group explained how it expects this to strengthen its current market position in global test commercialisation, the statement detailed.
"We are pleased to have delivered on both our operational and financial commitments, exceeding full year guidance, while continuing to invest in the long-term future of the Group,” added Keeling.
Follow News & Updates from Diaceutics here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
SP Angel research note on commodities and miners, featuring: Rio Tinto (RIO LN) – Q4 and 2019 production results highlight “value over volume” Sibanye-Stillwater - cuts close to 1,142 jobs at the Marikana platinum mines despite record palladium prices
The news follows two initial orders made by the group’s Nigerian distribution partner for a combined total of 250,000 tests in December which Omega said at the time remained conditional upon MOH’s approval of the test into Nigeria’s national HIV policy.
The London-listed group said this would put in place a framework of cooperation between itself and the CREHK-CRWE Joint Venture regarding future projects where they may work together.
“The process to finalise a tariff offer for submission to EDM is well underway and on track for submission in Q1 2020,” said Chief Executive, Hanno Pengilly, commenting on the power project which epitomises one of the fastest growing sectors in Africa today.
Paul Duffen, Executive Chairman of the Company, commented: "Having 100% ownership of Bet90 represents significant progress towards our stated objective to refocus the business on the core activity of online sportsbook and casino operations.”